Rosa Marina Melillo

List of Publications by Year
in descending order

87 papers	6,622 citations	61857 43 h-index	64668 79 g-index
124 all docs	124 docs citations	124 times ranked	7001 citing authors

#	Article	IF	Citations
1	In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. , 2022, 10, e004032.		25
2	The Impact of Resolution of Inflammation on Tumor Microenvironment: Exploring New Ways to Control Cancer Progression. Cancers, 2022, 14, 3333.	1.7	6
3	PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells. Journal of Experimental and Clinical Cancer Research, 2021, 40, 22.	3.5	37
4	Toll-Like Receptor 7 Mediates Inflammation Resolution and Inhibition of Angiogenesis in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 740.	1.7	8
5	AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer. Cancers, 2019, 11, 785.	1.7	27
6	Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies. F1000Research, 2019, 8, 227.	0.8	20
7	RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2). Endocrine-Related Cancer, 2018, 25, T105-T119.	1.6	19
8	New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution. Pharmacological Research, 2018, 128, 80-87.	3.1	31
9	Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways. OncoImmunology, 2017, 6, e1293213.	2.1	43
10	Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1. Journal of Biological Chemistry, 2017, 292, 1785-1797.	1.6	17
11	Interleukin-8, but Not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells. Stem Cells, 2017, 35, 135-146.	1.4	40
12	Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	11
13	Multiple anti-tumor effects of Reparixin on thyroid cancer. Oncotarget, 2017, 8, 35946-35961.	0.8	22
14	FRT â€“ FONDATION RENE TOURAINE. Experimental Dermatology, 2015, 24, 803-820.	1.4	0
15	The RET Receptor Family. , 2015, , 559-591.		1
16	Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8â€“Aktâ€“Slug pathway. Oncogene, 2015, 34, 5175-5186.	2.6	176
17	Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth. Pharmacological Research, 2015, 102, 184-191.	3.1	97
18	The genomic landscape of papillary thyroid carcinoma. Nature Reviews Endocrinology, 2015, 11, 133-134.	4.3	12

#	Article	IF	Citations
19	The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis. Oncogene, 2015, 34, 3826-3838.	2.6	69
20	AXL is an oncotarget in human colorectal cancer. Oncotarget, 2015, 6, 23281-23296.	0.8	55
21	Indoleamine 2,3-Dioxygenase 1 (IDO1) Is Up-Regulated in Thyroid Carcinoma and Drives the Development of an Immunosuppressant Tumor Microenvironment. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E832-E840.	1.8	73
22	Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation. Journal of Biological Chemistry, 2013, 288, 17481-17494.	1.6	44
23	Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. International Journal of Cardiology, 2013, 168, 1545-1547.	0.8	50
24	CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas. Modern Pathology, 2012, 25, 46-55.	2.9	35
25	Molecular Biomarkers in Thyroid FNA Samples. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4370-4373.	1.8	18
26	RET: A Multi-Faceted Gene in Human Cancer. Endocrinology and Metabolism, 2012, 27, 173.	1.3	1
27	Inflammation in thyroid oncogenesis. American Journal of Cancer Research, 2012, 2, 286-97.	1.4	25
28	Activation of TYRO3/AXL Tyrosine Kinase Receptors in Thyroid Cancer. Cancer Research, 2011, 71, 1792-1804.	0.4	87
29	Higher Intratumoral Expression of CD1a, Tryptase, and CD68 in a Follicular Variant of Papillary Thyroid Carcinoma Compared to Adenomas: Correlation with Clinical and Pathological Parameters. Thyroid, 2011, 21, 1209-1215.	2.4	39
30	Mast cells have a protumorigenic role in human thyroid cancer. Oncogene, 2010, 29, 6203-6215.	2.6	190
31	Thyroid cancer and inflammation. Molecular and Cellular Endocrinology, 2010, 321, 94-102.	1.6	186
32	CXC Chemokine Receptor 4 Immunodetection in the Follicular Variant of Papillary Thyroid Carcinoma: Comparison to Galectin-3 and Hector Battifora Mesothelial Cell-1. Thyroid, 2010, 20, 495-504.	2.4	24
33	Differential diagnosis of thyroid nodules using fine-needle aspiration cytology and oncogene mutation screening: are we ready?. F1000 Medicine Reports, 2010, 2, 62.	2.9	7
34	Interaction between HMGA1 and Retinoblastoma Protein Is Required for Adipocyte Differentiation. Journal of Biological Chemistry, 2009, 284, 25993-26004.	1.6	16
35	Helicobacter pylori Hp(2â€“20) Promotes Migration and Proliferation of Gastric Epithelial Cells by Interacting with Formyl Peptide Receptors In Vitro and Accelerates Gastric Mucosal Healing In Vivo. Journal of Immunology, 2009, 183, 3761-3769.	0.4	60
36	XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene, 2009, 28, 937-949.	2.6	59

#	Article	IF	Citations
37	Genetica molecolare del carcinoma tiroideo differenziato: implicazioni diagnostiche e terapeutiche. L Endocrinologo, 2009, 10, 114-118.	0.0	0
38	A New Germline Point Mutation in Ret Exon 8 (Cys⁵¹⁵Ser) in a Family with Medullary Thyroid Carcinoma. Thyroid, 2008, 18, 775-782.	2.4	27
39	A Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma. Cancer Research, 2007, 67, 10148-10158.	0.4	167
40	RET/Papillary Thyroid Carcinoma Oncogenic Signaling through the Rap1 Small GTPase. Cancer Research, 2007, 67, 381-390.	0.4	50
41	Receptor- and Non-Receptor Tyrosine Kinases Induce Processing of the Amyloid Precursor Protein: Role of the Low-Density Lipoprotein Receptor-Related Protein. Neurodegenerative Diseases, 2007, 4, 94-100.	0.8	7
42	Biological Role and Potential Therapeutic Targeting of the Chemokine Receptor CXCR4 in Undifferentiated Thyroid Cancer. Cancer Research, 2007, 67, 11821-11829.	0.4	100
43	OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. British Journal of Cancer, 2007, 97, 1545-1551.	2.9	32
44	RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. European Journal of Endocrinology, 2006, 155, 645-653.	1.9	176
45	Biochemical and molecular characterization of the novel BRAFV599Ins mutation detected in a classic papillary thyroid carcinoma. Oncogene, 2006, 25, 4235-4240.	2.6	56
46	Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene, 2006, 25, 5467-5474.	2.6	66
47	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell, 2006, 9, 459-471.	7.7	226
48	The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins. Cancer Research, 2006, 66, 6280-6287.	0.4	44
49	Activation of the Erk8 Mitogen-activated Protein (MAP) Kinase by RET/PTC3, a Constitutively Active Form of the RET Proto-oncogene. Journal of Biological Chemistry, 2006, 281, 10567-10576.	1.6	42
50	BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma. Clinical Cancer Research, 2006, 12, 1623-1629.	3.2	160
51	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	231
52	RAI(ShcC/N-Shc)-dependent recruitment of GAB1 to RET oncoproteins potentiates PI3-K signalling in thyroid tumors. Oncogene, 2005, 24, 6303-6313.	2.6	30
53	Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness. Clinical Cancer Research, 2005, 11, 8019-8027.	3.2	53
54	Osteopontin Is Overexpressed in Human Papillary Thyroid Carcinomas and Enhances Thyroid Carcinoma Cell Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5270-5278.	1.8	71

#	Article	IF	Citations
55	The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. Journal of Clinical Investigation, 2005, 115, 1068-1081.	3.9	126
56	Minireview: RET: Normal and Abnormal Functions. Endocrinology, 2004, 145, 5448-5451.	1.4	160
57	A New Germline RET Mutation Apparently Devoid of Transforming Activity Serendipitously Discovered in a Patient with Atrophic Autoimmune Thyroiditis and Primary Ovarian Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4810-4816.	1.8	18
58	Regulation of p27Kip1 Protein Levels Contributes to Mitogenic Effects of the RET/PTC Kinase in Thyroid Carcinoma Cells. Cancer Research, 2004, 64, 3823-3829.	0.4	45
59	Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene, 2004, 23, 2188-2196.	2.6	43
60	Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene, 2004, 23, 5958-5967.	2.6	119
61	The Oncogenic Activity of RET Point Mutants for Follicular Thyroid Cells May Account for the Occurrence of Papillary Thyroid Carcinoma in Patients Affected by Familial Medullary Thyroid Carcinoma. American Journal of Pathology, 2004, 165, 511-521.	1.9	35
62	Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes. Oncogene, 2003, 22, 246-255.	2.6	46
63	Protein kinase CÎ± activation by RET: evidence for a negative feedback mechanism controlling RET tyrosine kinase. Oncogene, 2003, 22, 2942-2949.	2.6	27
64	Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors. Oncogene, 2003, 22, 4569-4577.	2.6	67
65	Efficient Inhibition of RET/Papillary Thyroid Carcinoma Oncogenic Kinases by 4-Amino-5-(4-Chloro-Phenyl)-7-(t-Butyl)Pyrazolo[3,4-d]Pyrimidine (PP2). Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1897-1902.	1.8	115
66	The Neuron-Specific Rai (ShcC) Adaptor Protein Inhibits Apoptosis by Coupling Ret to the Phosphatidylinositol 3-Kinase/Akt Signaling Pathway. Molecular and Cellular Biology, 2002, 22, 7351-7363.	1.1	84
67	Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma. American Journal of Pathology, 2002, 160, 247-254.	1.9	103
68	Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27kip 1. Oncogene, 2002, 21, 1739-1749.	2.6	13
69	Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nature Medicine, 2002, 8, 1136-1144.	15.2	644
70	Molecular Mechanisms of RET Activation in Human Cancer. Annals of the New York Academy of Sciences, 2002, 963, 116-121.	1.8	137
71	Molecular Mechanisms of RET Activation in Human Neoplasia. , 2002, , 176-183.		0
72	The insulin receptor substrate (IRS)-1 recruits phosphatidylinositol 3-kinase to Ret: evidence for a competition between Shc and IRS-1 for the binding to Ret. Oncogene, 2001, 20, 209-218.	2.6	57

#	Article	IF	Citations
73	RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. Oncogene, 2001, 20, 6973-6982.	2.6	45
74	Docking Protein FRS2 Links the Protein Tyrosine Kinase RET and Its Oncogenic Forms with the Mitogen-Activated Protein Kinase Signaling Cascade. Molecular and Cellular Biology, 2001, 21, 4177-4187.	1.1	123
75	Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation. Molecular and Cellular Biology, 2001, 21, 2485-2495.	1.1	86
76	Tyrosines 1015 and 1062 Arein VivoAutophosphorylation Sites in Ret and Ret-Derived Oncoproteins¹. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3898-3907.	1.8	54
77	Pivotal Role of the RB Family Proteins in in Vitro Thyroid Cell Transformation. Experimental Cell Research, 2000, 260, 257-267.	1.2	10
78	Different mutations of the RET gene cause different human tumoral diseases. Biochimie, 1999, 81, 397-402.	1.3	12
79	Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKs): evidence for a divergence of the ERKs and JNKs pathways induced by Ret. Oncogene, 1998, 16, 2435-2445.	2.6	112
80	Molecular biology of the MEN2 gene. Journal of Internal Medicine, 1998, 243, 505-508.	2.7	42
81	Glial Cell Line-Derived Neurotrophic Factor Differentially Stimulates Ret Mutants Associated with the Multiple Endocrine Neoplasia Type 2 Syndromes and Hirschsprungâ€™s Disease1. Endocrinology, 1998, 139, 3613-3619.	1.4	32
82	The ret/ptc1 Oncogene Is Activated in Familial Adenomatous Polyposis-Associated Thyroid Papillary Carcinomas1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1003-1006.	1.8	82
83	The ret/ptc1 Oncogene Is Activated in Familial Adenomatous Polyposis-Associated Thyroid Papillary Carcinomas. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1003-1006.	1.8	49
84	Glial cell line-derived nenrotrophic factor (GDNF) stimulates ret activity. Rendiconti Lincei, 1997, 8, 139-149.	1.0	0
85	Molecular defects in thyroid carcinomas: Role of the RET oncogene in thyroid neoplastic transformation. European Journal of Endocrinology, 1995, 133, 513-522.	1.9	56
86	PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 1990, 60, 557-563.	13.5	905
87	Only the Substitution of Methionine 918 with a Threonine and Not with Other Residues Activates RET Transforming Potential. , 0, .		7